A5103037465- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Click Chemistry and Applications
- Synthesis and biological activity
- Coronary Interventions and Diagnostics
- Breast Cancer Treatment Studies
- Comparative International Legal Studies
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- Pharmacogenetics and Drug Metabolism
- Medical Imaging Techniques and Applications
- Cardiac Valve Diseases and Treatments
- Finance, Taxation, and Governance
- Colorectal Cancer Treatments and Studies
- Cardiac Imaging and Diagnostics
- Social Sciences and Policies
- Cancer Risks and Factors
- Radiomics and Machine Learning in Medical Imaging
- Acute Myocardial Infarction Research
- 14-3-3 protein interactions
- Inclusive Education and Diversity
- Cancer survivorship and care
- Aortic aneurysm repair treatments
- Nutritional Studies and Diet
GEICAM – Spanish Breast Cancer Group
2019-2024
MD Anderson Cancer Center Madrid
2021-2024
Centro Oncológico de Galicia
2012-2019
Institut Català d'Oncologia
2019
Compass Oncology
2019
Hospital Beatriz Ângelo
2019
Hospital Clínico Universitario de Valencia
2019
Texas Oncology
2019
Memorial Sloan Kettering Cancer Center
2019
Massachusetts General Hospital
2019
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. APHINITY trial (ClinicalTrials.gov identifier: NCT01358877 ) previously demonstrated pertuzumab added adjuvant...
The occurrence of balloon slippage ("watermelon seeding"; WMS) during treatment patients with in-stent restenosis (ISR) has been described, but predisposing factors and the potential implications this phenomenon remain unknown. In Restenosis Intrastent: Balloon Angioplasty vs. Elective Stenting (RIBS) randomized study, 450 ISR were included. Of these, 42 (9%) presented WMS procedure. was detected in 26 (12%) arm 16 (7%) stent (P=0.11). arm, only noticed predilation, never implantation. As...
Background. Physical activity has been demonstrated to increase survival in breast cancer patients, but few patients meet the general recommendations for physical activity. The aim of this pilot study was investigate if a supervised integrated counseling and group-based exercise program could leisure-time women with cancer. Methods. This project, designed as single-arm pre-post testing, consisted 24 classes combined aerobic strength training well on dietary health behavior. A total 48 who...
Abstract Purpose Breast cancer is an important health problem, like obesity and dyslipidemia, with a strong association between body mass index (BMI) breast incidence mortality. The risk of also high in women mammographic density (MBD). purpose this study was to analyze the BMI MBD according molecular subtypes. Methods This transversal, descriptive, multicenter conducted at three Spanish units from November 2019 October 2020 recent diagnosis early cancer. Data were collected time diagnosis....
With a prevalence of Morbid Obesity 1,2% the Spanish population, current criteria for Bariatric Surgery do not classify patients taking into consideration co-morbidities or functional status. We need new staging systems useful in predicting mortality and able to support prioritizing treatments.Applying Edmonton system awaiting Surgery.Data collected from 81 2011- 2013 after pre-surgery protocol. Weight, height, waist, BMI, biochemical parameters blood pressure are registered. Also taken down...
Abstract Background: B in combination with T has shown meaningful activity patients (pts) metastatic HER2-positive breast cancer. Pathological complete response (pCR) was defined as the absence of invasive disease at time histological study and there is a relationship between pCR disease-free survival (DFS) overall (OS). The pathological rate 9 to 34% receiving primary treatment prior surgery chemotherapy when Herceptin administrated, 39% reached. AVANTHER Phase II trial preoperative...